-
April 18, 2012
ALK Mutation Testing for NSCLC on the Rise among Oncologists, BioTrends Survey Finds
A recent survey tracking the adoption of ALK mutation testing among oncologists suggests that doctors are becoming increasingly comfortable personalizing treatment strategies for non-small cell lung cancer patients based on clinical factors and genomic data.
-
March 22, 2012
The Impact of Bundling on Clinical Practice
The implementation of a bundled payment system for chronic dialysis in January 2011 was not a surprise and has not been associated with a radical change in clinical practice.
-
February 14, 2012
On 9th February 2012, the FDA finally published draft guidance addressing the over-arching requirements for biosimilar medicines to gain approval in the United States.
Contributor: Dr. Andrew Merron
-
August 2, 2011
Research and Markets: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
Research and Markets has announced the addition of Decision Resources, Inc.'s new report "Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases" to their offering.
-
March 27, 2010
Cost Cutting Isn’t the Answer to Bundling Meds
The recent Bio-trends Research Group Special Report: Impact of the Dialysis Bundles Payment System doesn’t present a pretty picture of what dialyzors may face when bundling takes effect.
-
January 29, 2010
Future Iron Treatments Shaped by New Payment Structures, Products
The strategy seems to be slow but steady growth. Few nephrologists have reported using AMAG Pharmaceutical’s Feraheme in the months since its launch; however, a number of them said they are “on the verge” of using the new iron drug, according to survey results released last November from BioTrends Research Group.
-
September 10, 2009
BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time
For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.